Serum neurofilament light chain in progressive supranuclear palsy

Laura Donker Kaat; Lieke H. Meeter; Wan Zheng Chiu; Shami Melhem; Agnita J. W. Boon; Kaj Blennow; Henrik Zetterberg; John C. van Swieten

doi:10.1016/j.parkreldis.2018.06.018

Serum neurofilament light chain in progressive supranuclear palsy

Laura Donker Kaat, Lieke H. Meeter, Wan Zheng Chiu, Shami Melhem, Agnita J. W. Boon, Kaj Blennow, Henrik Zetterberg, John C. van Swieten

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction: Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases. Elevated NfL levels in CSF and blood have been observed in a growing number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) in relation to disease severity and survival. Methods: Serum NfL levels were determined cross-sectionally in a retrospective cohort of 131 patients with PSP and 95 healthy controls. Detailed clinical examination was performed and disease severity was assessed by several rating scales. Results: We found that serum NfL levels in PSP were twice as high as those in controls, and that NfL levels correlated with worse functional, motor and cognitive functioning. During follow-up, 119 PSP patients had died, and higher NfL levels were associated with a shorter survival. Conclusion: This study provides evidence that serum NfL is a relevant and promising biomarker in PSP for disease severity, and may be used as a prognostic tool to predict survival in clinical practice.

Original language	English
Pages (from-to)	98-101
Number of pages	4
Journal	Parkinsonism and Related Disorders
Volume	56
Early online date	2018
DOIs	https://doi.org/10.1016/j.parkreldis.2018.06.018
Publication status	Published - 1 Nov 2018

Access to Document

10.1016/j.parkreldis.2018.06.018

Cite this

Donker Kaat, L., Meeter, L. H., Chiu, W. Z., Melhem, S., Boon, A. J. W., Blennow, K., ... van Swieten, J. C. (2018). Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism and Related Disorders, 56, 98-101. https://doi.org/10.1016/j.parkreldis.2018.06.018

@article{7c60afe9021e404c8d8203d2f3d78bea,

title = "Serum neurofilament light chain in progressive supranuclear palsy",

abstract = "Introduction: Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases. Elevated NfL levels in CSF and blood have been observed in a growing number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) in relation to disease severity and survival. Methods: Serum NfL levels were determined cross-sectionally in a retrospective cohort of 131 patients with PSP and 95 healthy controls. Detailed clinical examination was performed and disease severity was assessed by several rating scales. Results: We found that serum NfL levels in PSP were twice as high as those in controls, and that NfL levels correlated with worse functional, motor and cognitive functioning. During follow-up, 119 PSP patients had died, and higher NfL levels were associated with a shorter survival. Conclusion: This study provides evidence that serum NfL is a relevant and promising biomarker in PSP for disease severity, and may be used as a prognostic tool to predict survival in clinical practice.",

author = "{Donker Kaat}, Laura and Meeter, {Lieke H.} and Chiu, {Wan Zheng} and Shami Melhem and Boon, {Agnita J. W.} and Kaj Blennow and Henrik Zetterberg and {van Swieten}, {John C.}",

year = "2018",

month = "11",

day = "1",

doi = "10.1016/j.parkreldis.2018.06.018",

language = "English",

volume = "56",

pages = "98--101",

journal = "Parkinsonism and Related Disorders",

issn = "1353-8020",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Serum neurofilament light chain in progressive supranuclear palsy

AU - Donker Kaat, Laura

AU - Meeter, Lieke H.

AU - Chiu, Wan Zheng

AU - Melhem, Shami

AU - Boon, Agnita J. W.

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - van Swieten, John C.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Introduction: Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases. Elevated NfL levels in CSF and blood have been observed in a growing number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) in relation to disease severity and survival. Methods: Serum NfL levels were determined cross-sectionally in a retrospective cohort of 131 patients with PSP and 95 healthy controls. Detailed clinical examination was performed and disease severity was assessed by several rating scales. Results: We found that serum NfL levels in PSP were twice as high as those in controls, and that NfL levels correlated with worse functional, motor and cognitive functioning. During follow-up, 119 PSP patients had died, and higher NfL levels were associated with a shorter survival. Conclusion: This study provides evidence that serum NfL is a relevant and promising biomarker in PSP for disease severity, and may be used as a prognostic tool to predict survival in clinical practice.

AB - Introduction: Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases. Elevated NfL levels in CSF and blood have been observed in a growing number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) in relation to disease severity and survival. Methods: Serum NfL levels were determined cross-sectionally in a retrospective cohort of 131 patients with PSP and 95 healthy controls. Detailed clinical examination was performed and disease severity was assessed by several rating scales. Results: We found that serum NfL levels in PSP were twice as high as those in controls, and that NfL levels correlated with worse functional, motor and cognitive functioning. During follow-up, 119 PSP patients had died, and higher NfL levels were associated with a shorter survival. Conclusion: This study provides evidence that serum NfL is a relevant and promising biomarker in PSP for disease severity, and may be used as a prognostic tool to predict survival in clinical practice.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85048853432&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29937097

U2 - 10.1016/j.parkreldis.2018.06.018

DO - 10.1016/j.parkreldis.2018.06.018

M3 - Article

C2 - 29937097

VL - 56

SP - 98

EP - 101

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -